NGeneBio Co (354200.KQ) Osake Kurssi

NGeneBio Co., Ltd. engages in the research and development of diagnostic products related to cancer. The company is headquartered in Seoul, Seoul. The company went IPO on 2020-12-10. The firm's main products include BRCAaccuTest products used for hereditary breast and ovarian cancer testing, HEMEaccuTest products that tests the causative genes related to blood cancer such as leukemia, lymphoma, and bone marrow cancer, SOLIDaccuTest products that test the causative genes of solid cancer tissues such as lung cancer, colon cancer and stomach cancer. In addition, the Company manufactures and sells products of HLAaccuTest products that tests tissue-specific antigens used for bone marrow transplantation, ONCOaccuPanel products for precise diagnosis of large-capacity solid cancer, HEREDaccuTest products for precise diagnosis for rare diseases. The firm also provides services such as genetic testing direct to customer(DTC) and personalized healthcare.